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INTRODUCTION
In recent years, opportunities to use contrast
media have increased with improvements in various
diagnostic imaging methods, including CT and
angiography, as well as in intra-arterial therapy.
Non-ionic contrast media with low osmotic pressure,
including iomeprol, have been developed and come
into use because they have less pronounced biolog-
ical effects than conventional ionic contrast media
with high osmotic pressure(1-4). All contrast media,
however, are foreign matter to patients and experi-
mental animals, and their use involves the risk of
provoking adverse reactions, such as iododerma
and nephrotoxicity (5,6). Since contrast media are
mostly excreted in urine via the kidneys, they may
accumulate in patients with renal failure (7,8).
Furthermore, it has been reported that necrosis of
the pancreas in the acute necrotic pancreatitis rat
model exacerbated following the administration of a
contrast medium (9) and that a patient with severe
acute necrotic pancreatitis who underwent contrasted
CT showed worsened prognosis (10). Therefore,
contrast media should be used very carefully in
patients with renal function disorders or necrotic
lesions. Taking these findings into consideration,
the supplementary removal of contrast media in
blood appears to be highly desirable. Various blood
purification therapies, such as hemodialysis (HD),
hemofiltration (HF), and hemodiafiltration (HDF),
are currently performed for patients with renal failure
(11-13). HD, which may result in a decrease in blood
pressure due to the rapid removal of solutes, is
difficult to perform for seriously ill patients with
multiple organ failure who frequently present with
unstable hemodynamics (14). By contrast, HF has
less effect on hemodynamics than HD (11). However,
HF alone is not sufficient for removing substances
of low molecular weight. For this reason, HDF, a
method by which the dialysate circulates outside
the HF filter and which has the advantages of both
HD and HF, has been introduced (12, 13). HF and
HDF are usualy performed for several hours at high
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flow rates with a large membrane area hemofilter.
For critically ill patients with unstable hemodynamics,
HF and HDF are often performed continuously at low
flow rates with a small membrane area hemofilter
[continuous hemofiltration (CHF) and continuous
hemodiafiltration (CHDF)] to prevent a decrease
in blood pressure and to continuously correct the
water and electrolyte balance (15, 16). Contrast media
with a molecular weight of less than 1,300 daltons
have very low protein binding rates and are regarded
as substances which are removable by HD (17-20).
However, no in-depth studies have been made to date
on the contrast medium-removing ability of blood
purification therapies other than HD. In this study
we investigate the efficacy of HF and HDF, at low
flow rates with a small membrane area hemofilter,
to remove iomeprol, a non-ionic contrast medium
with low osmotic pressure. In addition, we studied
the mechanism by which these therapies remove
iomeprol.
MATERIALS AND METHODS
A solution containing 140 milliliters of citrate-
phosphate-dextrose (CPD) (21) was added to 1 liter
of bovine blood immediately after collection, and the
hematocrit and total protein of the mixture were
adjusted to 38% and 6.0 g/dl, respectively, before the
start of the present study. Four liters of the adjusted
bovine blood was poured into a tank and warmed
at 36℃ while being stirred with a stirrer (Figure 1).
The console used for HF and HDF was a KM-8800
(Kuraray Co., Ltd., Osaka, Japan), and the filter : a
polysulfone hemofilter (PS filter-CF ; membrane
area : 0.7  ; Kuraray). The replacement fluid and
dialysate consisted of commercial replacement fluid
which had previously been mixed with the CPD
solution to obtain a concentration which was com-
parable to actual blood concentration. The bulk of
the nafamostat mesilate (Torii Pharmaceutical Co.,
Ltd., Tokyo, Japan) was dissolved in the 5% glucose
solution to obtain a concentration of 10 mg/ml, and
the material was administered as an anticoagulant
at a dose of 3 ml/hr (30 mg/hr) before filtration.
The test materials were divided into the following
four groups : Group I (high flow rate HDF group,
n=4) which underwent HDF at a blood flow rate
(QB) of 100 ml/min, a replacement fluid flow rate
(QF) of 10 ml/min, and a dialysate flow rate (QD) of
40ml/min ; Group II (HDF group, n=4) which under-
went HDF at a QB of 100 ml/min, a QF of 10 ml/
min, and a QD of 10 ml/min ; Group III (HF group,
n=4) which underwent HF at a QB of 100 ml/min,
and a QF of 10 ml/min ; and Group IV (control group,
n=4) for which no blood purification method was
used, and the blood in the tank was only stirred.
A non-ionic contrast medium with low osmotic
pressure, iomeprol (612.4 mg/ml ; iodine content :
300mgI/ml ; molecular weight : 777 ; protein binding
rate : 0% ; Eisai Co., Ltd., Tokyo, Japan) was used
in the present study. Iomeprol was administered
by one injection into the tank at 30 min after the
start of HF and HDF. A 5-ml blood sample was
collected in the afferent and efferent tubes, and a
5-ml waste fluid sample was collected in the drainage
tube on a time-course basis (at 5 and 30 min, as well
as at 1, 2, 4, and 6 hr after administration). These
samples were centrifuged at 3,000 rpm for 10 min,
and the isolated plasma and waste fluid were stored
at -20℃ until the determination of iomeprol concen-
trations by high-performance liquid chromatography
(HPLC).
The pharmacokinetic parameters were calculated,
and data were analyzed with the least square method.
Blood half-lives and elimination rates of iomeprol
were calculated according to the following formulas:
Half-life (hr) = Ke / AUC ;
Elimination rate (%) = [Ca(t5)-Ca(t)]/Ca(t5)×100,
where Ke is the elimination rate constant, AUC
is the area under the curve, Ca (t5) is the blood
iomeprol concentration in the afferent tube 5 min
Fig.1. Schema of HDF (A) and HF (B) using a bovine blood
tank. Four liters of the adjusted bovine blood was poured into a
tank and warmed at 36℃ while being stirred with a stirrer. For
HDF and HF, a PS filter CF (membrane area : 0.7 ) was used.
Five ml of blood was collected in the afferent tube () and in
the efferent tube (), and 5 ml of waste fluid was collected in
the drainage tube (). a : anticoagulant solution (10 mg/ml
nafamostat mesilate solution), b : waste fluid, c : dialisate fluid,
d : replacement fluid. QB : blood flow rate, QF : replacement
fluid flow rate, QD : dialysate flow rate.
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after administration, and Ca(t) is the same concen-
tration at t hours.
To investigate the elimination rate of iomeprol into
the waste fluid and the adsorption rate on the HDF
filter, the sieve coefficients, clearance rates, and
adsorption rates of iomeprol were calculated according
to the following formulas :
Sieve coefficient = Cd(t)/Ca(t) ;
Clearance rate (ml/min) = [Ca(t)-Cv(t)]/Ca(t)×QB;
Adsorption rate (%) = {[Ca(t)-Cv(t)]/Ca(t)-Cd(t)
×(QF+QD)/Ca(t)/QB}×100,
where Cd(t) is the iomeprol concentration in thewaste
fluid in the drainage tube at t hr after administration,
Ca(t) is the iomeprol concentration in blood in the
afferent tube at t hr after administration, Cv(t) is
the iomeprol concentration in blood in the efferent
tube at t hr after administration, QB is the blood
flow rate, QF is the replacement fluid flow rate, and
QD is the dialysate fluid flow rate.
For statistical analysis, blood iomeprol concen-
trations were expressed as the geometric mean±
geometric SE, and other data were expressed as
the mean or the mean±SD. Blood concentrations
and parameters obtained for each model were com-
pared by analysis of variance (repeated ANOVA)
and Wilcoxon's rank sum test. A difference was
considered statistically significant at a P value <0.05.
RESULTS
Five minutes after administration, the blood iomeprol
concentration for Group IV (control group) was
41.0±0.2 mg/ml and no significant change was
seen in this level. A semilogarithmic fit made of the
concentration versus time data yielded a linear elim-
ination curve for iomeprol in the blood purification
groups (Figure 2). The blood purification groups
showed a decrease in blood iomeprol concentra-
tions, yielding the following half-lives : 1.0±0.04 hr
for Group I (high flow rate HDF group) ; 1.8±0.1hr
for Group II (HDF group) ; and 3.8±0.1 hr for
Group III (HF group). Significant differences were
seen in the kinetics of iomeprol concentration in
the 4 groups (p<0.001). Four hours after admin-
istration, the blood iomeprol concentrations were
2.8±0.4 mg/ml for Group I, 9.7±1.2 mg/ml for
Group II, and 17.9±0.4 mg/ml for Group III and,
6 hrs after administration, the corresponding con-
centrations were 0.7±0.1 mg/ml, 4.3±0.8 mg/ml,
and 12.3±0.6 mg/ml, respectively.
Four hours after administration, the elimination
rates were 93.1±1.2% for Group I, 75.4±2.8% for
Group II, and 51.1±1.0% for Group III and, 6 hrs
after administration, the corresponding rates were
98.4±0.4%, 88.1±1.6%, and 66.3±1.8% respectively
(Figure 3). Significant differences were seen in the
elimination rates of iomeprol from the blood in the
4 groups (p<0.001). The elimination rates were sig-
nificantly higher in Group I than in Groups II and
III (p<0.001), and in Group II than in Group III
(p<0.001).
No changes were observed in sieve coefficient,
clearance rate, or adsorption rate. The mean sieve
coefficients were 0.73±0.07 for Group I, 0.90±0.10
for Group II, and 1.04±0.05 for Group III. The
corresponding mean clearance rates were 39.7±
Fig.2. Time course of blood iomeprol concentration after the
start of HDF or circulation for the high flow rate HDF group
(●), the HDF group (○), the HF group (■), and the control
group (□). Data represent the geometric mean±geometric SE
(n=4).
Fig.３. Elimination rates of blood iomeprol concentration after
the start of HDF or circulation for the high flow rate HDF group
(●), the HDF group (○), the HF group (■), and the control
group (□). Data represent the mean±SD (n=4).
The Journal of Medical Investigation Vol.45 1998 ８９
2.8ml/min, 21.4±4.0ml/min, and 12.0±1.1ml/min,
respectively. As shown in Table 1, the clearance
rates were significantly higher in Group I than in
Groups II and III, and in Group II than in Group
III. The adsorption rate accounted for 1.5 to 6.9%,
and no significant differences were seen among the
3 groups.
DISCUSSION
CHF and CHDF have been used for critically ill
patients with unstable hemodynamics to correct the
imbalance of water and electrolytes (15, 16) and, in
some reports, these therapies have been described
as effective in removing chemical mediators related
to the development of multiple organ failure (22, 23).
HD removes substances of low molecular weight
from blood by diffusion, and the clearance rate by
HD is inversely proportional to the square root of
the molecular weight of the substance in question
(24). HF, on the other hand, filtrates substances of
medium molecular weight (MW : <30,000 daltons)
from blood by negative pressure (25). Thus, HF is
generally more effective than HD in removing sub-
stances of medium molecular weight (MW:≧300 to
30,000 daltons) (26). However, the recent development
of dialyzers with a high performance membrane has
enabled substances of medium molecular weight
(MW : <10,000) to be removed by HD as well (27).
Iomeprol is a substance of medium molecular weight
(MW : 777), with a very low protein binding rate,
and a very low accumulation rate in tissue (8).
Therefore, it has been reported that iomeprol can
be removed from blood to the same extent in
critically ill patients as in healthy subjects by HD,
a method which utilizes a new type of dialyzer with
a large membrane area consisting of a high perfor-
mance membrane which can remove substances
of medium molecular weight (MW : <10,000) (17).
HDF has the advantages of both HD and HF,
and has greater ability to remove substances of low
molecular weight than HF (12,13). In the present
study, HDF removed iomeprol more effectively than
HF at the same blood and replacement fluid flow
rates (QB : 100ml/min ; and QF : 10ml/min). In blood
purification therapy, the removal of a substance in
blood is achieved not only by excretion in waste fluid
but also by adsorption to membranes. However, the
percentage of iomeprol removed by adsorption to
membranes was less than 7%. Clearly, iomeprol was
mostly excreted in waste fluid. The sieve coefficient,
the ratio of the waste fluid iomeprol level to that of
the blood, was 1.0 for the HF group. Therefore, it was
considered that the efficacy of HF in the removal
of iomeprol could be improved by increasing QB
and QF, the latter nearly to QF max. Although the
sieve coefficient is lowered by an increase in the
QD of HDF, the clearance of iomeprol by HDF
should be further enhanced by an increase in the
QD since the volume of iomeprol excreted in the
waste fluid will increase.
Contrast media administered to patients are mostly
excreted in unchanged form in urine via the kidneys
(7). Following the intravenous administration of 40
and 80 ml of iomeprol (816.5 mg/ml ; iodine content,
400mgI/ml) to healthy volunteers at a dose of 10ml/
min, the blood half-life of iomeprol was 1.95 hr. Two
Table 1. Sieving coefficients, clearance rates, and adsorption rates of iomeprol after passage through the circuit at 2, 4,
and 6 hrs after administration (n=4 for each group)
Time Group Sieving coefficient Clearance rate(ml/min)
Adsorption rate
(%)
2 hr
Group I
Group II
Group III
0.75±0.08＊†††
0.92±0.07††
1.04±0.03＊＊
40.3±1.1＊†††
21.3±1.6††
11.9±0.8＊＊
2.9±4.7
2.9±2.4
1.5±1.1
4 hr
Group I
Group II
Group III
0.71±0.04＊＊††
0.99±0.06
1.01±0.09
41.8±1.8＊†††
23.0±3.2††
11.1±0.6＊＊
6.2±3.1
3.2±3.7
1.0±1.0
6 hr
Group I
Group II
Group III
0.75±0.01††
0.94±0.14
1.05±0.03
39.1±5.0＊†††
25.6±1.6††
12.6±1.8＊＊
1.7±4.9
6.9±4.1
2.1±1.6
Group I : high flow rate HDF group, Group II : HDF group, Group III : HF group, * : P<0.05 vs. Group II, ** : P<0.01 vs.
Group II, †† : P<0.01 vs. Group III, ††† : P<0.005 vs. Group III
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hours after administration, about 50% of the iomeprol
administered was excreted in urine and, at 4hr, about
80% (8). In the present study, the blood half-life of
iomeprol was 1.0 hr for the high flow rate HDF group
and 1.8 hr for the HF group. The elimination rate
of blood iomeprol, 4 hrs after administration, was
93.1% for the high flow rate HDF group, and 75.4%
for the HDF group. It is predicted that the blood
half-life and the elimination rate of HDF (QB:100ml/
min ; QF : 10 ml/min ; and QD : 10 ml/min) would
be comparable to that of healthy adults, and those
of high flow rate HDF (QB : 100ml/min ; QF : 10ml/
min ; and QD : 40ml/min) superior to that of healthy
adults (8). A small volume (4 liters) of blood and a
tank model were used in the present study, and the
efficacy of iomeprol removal from blood only was
assessed using a one-compartmentmodel. As such, the
effect of the distribution of iomeprol into extracellular
fluids could not be taken into consideration. Con-
sequently, it can be assumed that the half-lives and
decreases in iomeprol following HF and HDF in
clinical cases would be lower than the results obtained
in the present study.
While the contrast medium-removing ability of
HF or HDF in clinical cases has not been reported
to date, several reports have described the efficacy
of HD in the removal of contrast media. Generally,
it can be predicted that more than 80% of a contrast
medium administered is eliminated by HD which
uses a dialyzer with a large membrane area at a
blood flow rate of 200 ml/min. Ueda et al. have
reported the efficacy of HD (QB : 200 ml/min and
QD : 500 ml/min) using a hollow fiber dialyzer with
an acetate cellulose diacetate membrane (membrane
area : 2.1 ) in the removal of iomeprol (714.4mg/ml ;
iodine content : 350 mgI/ml) from patients with
chronic renal failure (17). The clearance rate of
iomeprol for the high flow rate HDF group was
about 40 ml/min, i.e., about one-third the clearance
rate (130 ml/min) of iomeprol by HD reported by
Ueda et al (17). The clearance rate of a contrast
medium is dependent upon its quality (molecular
weight and protein binding rate), filter (material,
type, and membrane area), and flow rate parameters
(QB, QF, and QD). In the present study, the rate of
iomeprol clearance by HF and by HDF was
inferior to that by HD. This result was attributed
to the following : 1) QB, QD, and QF of HF and
HDF were set at low levels similar to CHF and
CHDF cases ; and 2) a hemofilter with a smaller
membrane area was used.
Despite the fact that newly developed low-osmolar
and non-ionic contrast media affect renal function
to a lesser extent and are better tolerated than con-
ventional media (1-4), acute renal failure caused
by these new contrast media has been reported (28,
29). The incidence of renal damage after angiographic
procedures was reported to be over 20% in patients
with a serum creatinin above 2mg/dl (30-32) and over
70% in diabetes mellitus patients with an abnormal
renal function (33, 34). For this renal damage, stan-
dard conservative prophylactic therapies are not
effective (32, 33, 35). Moon et al. reported that no
further impairment of renal function was observed
following the use of HD in any of 7 high-risk patients
of developing contrast media nephropathy : serum
creatinin above 4.5 mg/dl in 7 patients, diabetes
mellitus in 5 patients, hypertension in 6 patients
(36). They suggested that accelerated elimination of
contrast media by prophylactic HD can be benefical
in preventing further reduction in renal function
after angiographic procedures in high-risk patients.
On the other hand, Younathan et al. reported that
after examinations with contrast media performed
between regular HD in end-stage renal disease,
there was no significant change in blood pressure,
ECG, total serum protein, osmolarity, extracellular
fluid volume, or body weight (37). They concluded that
immediate dialysis after administration of non-ionic
contrast agents is not necessary.
Continuous intra-arterial administration of a protease
inhibitor to patients with severe acute necrotic
pancreatitis has been used as an effective therapy
(38, 39). However, it is necessary to confirm the
necrotic area of the pancreas with contrasted CT
before conducting this therapy, and the use of a
contrast medium carries the risk of exacerbating
renal function and necrosis of the pancreas (9, 10).
The effects of contrast media on patients and exper-
imental animals have not been examined in sufficient
detail. The effects of accelerated elimination of contrast
media by prophylactic blood purification therapies
on necrotic lesions have not been examined. It is,
therefore, necessary not only to investigate the effects
of contrast media on patients and experimental
animals but also to determine the time points and
rates at which they should be removed from blood
after administration. Furthermore, randomized control
studies should be performed to evaluate the benefical
effects of early contrast media removal in preventing
side effects of contrast media .
We consider that HDF, at low flow rates with a
small membrane area hemofilter, is a method which
has less effect on hemodynamics and, as such, can
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remove contrast media more safely in patients
with unstable hemodynamics than HD and more
effectively than HF. We found that the contrast
medium-removing ability of HF and HDF, at low
flow rates with a small membrane area hemofilter,
is never superior to that of HD.However, the contrast
medium-removing ability of HF and HDF would
probably be improved, as compared with the result
of the present study, by setting the blood flow rate,
dialysate flow rate, and replacement fluid flow rate
higher and by using a hemofilter with a larger mem-
brane area. It is generally felt that opportunities to
use contrast media for patients with renal function
disorders or necrotic lesions will increase and that
contrast media will be used more frequently for
patients with unstable hemodynamics. We consider
that it is possible to remove contrast mediamore safely
and effectively by selecting the blood purification
therapy most suited to a particular pathological
process.
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